Stockscreener 앱 받기
60.73
3.66%
-2.31
시간 외 거래:
61.51
0.78
+1.28%
전일 마감가:
$63.04
열려 있는:
$61.1
하루 거래량:
4.90M
Relative Volume:
2.20
시가총액:
$6.38B
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+16.45%
1개월 성능:
+17.01%
6개월 성능:
+136.76%
1년 성능:
+0.00%
1일 변동 폭
$60.37
$61.85
1주일 범위
$51.84
$66.10
52주 변동 폭
$12.30
$66.10
Metsera Inc Stock (MTSR) Company Profile
명칭
Metsera Inc
전화
(212) 784-6595
주소
3 WORLD TRADE CENTER, NEW YORK
MTSR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MTSR
Metsera Inc
|
60.73 | 6.63B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Metsera Inc Stock (MTSR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-30 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2025-09-09 | 개시 | Leerink Partners | Outperform |
| 2025-06-20 | 개시 | Wells Fargo | Overweight |
| 2025-02-25 | 개시 | BofA Securities | Buy |
| 2025-02-25 | 개시 | Evercore ISI | Outperform |
| 2025-02-25 | 개시 | Guggenheim | Buy |
모두보기
Metsera Inc 주식(MTSR)의 최신 뉴스
Key facts: Novo Nordisk Q3 revenue up 9.4%; bids $8.5B for Metsera; Hims launches semaglutide - TradingView
Why Pfizer Can Still Prevail in the Obesity Fight With Novo NordiskWSJ - The Wall Street Journal
Pfizer accuses Novo Nordisk of anticompetitive plot to stall Metsera deal in lawsuit - Reuters
Pfizer’s And Novo’s Competing Bids For Metsera Devolve Into Lawsuits, Name Calling - Citeline News & Insights
ACQUISITIONS & MERGERS NEWS: Pfizer sues Metsera and Novo Nordisk to halt their proposed merger - VitalLaw.com
Pfizer, Novo's Metsera war could redraw the map for obesity treatments - Axios
Pfizer Hits Novo Nordisk In Fed. Court Over $9B Metsera Deal - Law360
Metsera, Inc. Responds to Pfizer’s Litigation Claims - MSN
Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo - Investor's Business Daily
Pfizer Sues Novo, Metsera for Second Time in Brewing Deal War - Bloomberg.com
Pfizer Lawsuits Allege Novo Nordisk’s Bid to Buy Obesity Biotech Metsera is Anticompetitive, Illegal - MedCity News
Market Voices: Pfizer-Novo Nordisk legal battle; Trump on Zhao pardon - MSN
Pfizer Files Lawsuits Against Metsera and Novo Nordisk - Pharmaceutical Executive
Coinbase Said Web3 - Bloomberg.com
Pfizer sues to block Novo Nordisk bid for obesity drug maker Metsera - The Business Journals
Pfizer files US court challenge to Novo's bid for Metsera - MLex
FinCEN Offers Relief to Banks on ‘Overwhelming’ SARs Filings - PYMNTS.com
Pfizer files second lawsuit against Metsera, Novo Nordisk - whbl.com
Novo Nordisk’s Attempt to Buy Metsera is Anticompetitive, Says Pfizer in Second Lawsuit - TipRanks
Pfizer Q3 Earnings Preview: Results to test recovery hopes amid TrumpRx deal, Metsera dispute - MSN
Metsera rejects Pfizer litigation as attempt to lower acquisition price - Investing.com
Pfizer sues Novo, Metsera for second time in brewing deal war - Crain's New York Business
Metsera issues statement regarding Pfizer litigation and proposed acquisition By Investing.com - Investing.com UK
Metsera issues statement regarding Pfizer litigation and proposed acquisition - Investing.com
Novo Nordisk says Metsera bid won’t raise antitrust issues By Reuters - Investing.com
Pfizer Q3 Earnings Preview: Results to test recovery hopes amid TrumpRx deal, Metsera dispute (PFE:NYSE) - Seeking Alpha
Novo Nordisk says Metsera bid won't raise antitrust issues - Reuters
Pfizer Files Antitrust Suit to Block Novo Nordisk Acquisition of Metsera - The Wall Street Journal
Pfizer Aligns With Trump on Drug Pricing In Its Bid for Biotech Metsera - Barron's
Novo Nordisk spokesperson says Pfizer's claims against co's Metsera offer is "without merit" - MarketScreener
Another Pfizer lawsuit to stop Novo bid for Metsera - The Pharma Letter
Pfizer files second lawsuit against Novo Nordisk, Metsera in bidding war over obesity biotech - CNBC
Pfizer Files Antitrust Lawsuit Against Metsera, Its Controlling Stockholders And Novo Nordisk - Nasdaq
Metsera Responds to Pfizer's Legal Action Amid Bid Interest from Novo Nordisk (NVO) - GuruFocus
Metsera to address Pfizer's litigation in court - MarketScreener
Metsera Issues Statement in Response to Litigation - Yahoo Finance
UPDATE: Pfizer Files Lawsuits Against Novo Nordisk, Metsera To Stop Rival Bid - BioSpace
How to build a custom watchlist for Metsera Inc.Market Growth Summary & Weekly Setup with High ROI Potential - newser.com
Is Metsera Inc. stock entering bullish territory2025 Dividend Review & Community Supported Trade Ideas - newser.com
Pfizer files two lawsuits to stop Novo's $9B buyout of Metsera - BioWorld MedTech
Is Metsera Inc. stock a safe investment in uncertain marketsTrade Entry Summary & Reliable Trade Execution Plans - newser.com
Pfizer files another lawsuit: Accuses Metsera owners of conspiring with Novo Nordisk - medwatch.com
Metsera falls after Pfizer files a second lawsuit against co and Novo - TradingView
How currency fluctuations impact Metsera Inc. stockJuly 2025 Summary & Proven Capital Preservation Tips - newser.com
Pfizer (PFE) Files Lawsuit Against Novo Nordisk Over Metsera Bid - GuruFocus
Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle - Benzinga
The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit - MSN
Pfizer files second lawsuit to block Novo Nordisk’s $9bn Metsera bid - Financial Times
Pfizer files second lawsuit against Novo Nordisk, Metsera in battle over obesity startup - statnews.com
Pfizer sues Novo Nordisk and Metsera once againbid considered to restrict competition - MarketScreener
Why Metsera Inc. stock appeals to analystsEntry Point & Advanced Technical Signal Analysis - newser.com
Metsera Inc (MTSR) 재무 분석
Metsera Inc (MTSR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
0.64%
0.35%
자본화:
|
볼륨(24시간):